美农生物 (301156.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

23.5x

Market Cap

CNY 2.10B

MomentumView details →

1D Return

−2.64%

YTD Return

−29.01%

RSI (14)

57.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

23.5x

Market Cap

CNY 2.10B

RSI (14)

57.4

MomentumView details →

1D Return

−2.64%

YTD Return

−29.01%

ProfitabilityView details →

Gross Margin

31.26%

Net Margin

9.57%

EBITDA Margin

14.53%

ROE (TTM)

7.94%

ROA (TTM)

6.88%

Asset Turnover

0.73x

GrowthView details →

Revenue YoY

+26.14%

EPS YoY

+23.89%

FCF YoY

—

Revenue CAGR 3Y

+5.11%

EPS CAGR 3Y

−10.12%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.00x

Quick Ratio

2.98x

Div Yield

2.90%

Div Rate

CNY 0.36

Div Growth 1Y

+12.50%

Financials snapshotView financials →

Revenue (TTM)

620.44M

Net Income (TTM)

59.38M

Op. CF (TTM)

35.92M

Latest newsMore news →

Meinong Bio announced its first-half 2026 results: revenue of 328 million yuan, up 38.71% year-on-year, and net profit attributable to shareholders of 18.061 million yuan, down 23.23% year-on-year.10d ago

Similar companies

百洋股份002696.SZ 嘉麟杰002486.SZ 摩登大道002656.SZ 扬帆新材300637.SZ 趣睡科技301336.SZ 富邦科技300387.SZ Find similar companies →

Latest newsMore news →

Meinong Bio announced its first-half 2026 results: revenue of 328 million yuan, up 38.71% year-on-year, and net profit attributable to shareholders of 18.061 million yuan, down 23.23% year-on-year.10d ago